| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/17/2002 | EP1196616A2 Replication-competent anti-cancer vectors |
| 04/17/2002 | EP1196610A2 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| 04/17/2002 | EP1196609A2 Catalytically active recombinant memapsin and methods of use thereof |
| 04/17/2002 | EP1196600A1 Drosophila recombination-associated protein and methods for use |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196595A2 Methods of inducing cell death |
| 04/17/2002 | EP1196579A2 Tryptase inhibitor |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196564A2 Atherosclerosis-associated genes |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196559A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 04/17/2002 | EP1196442A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196438A1 A ligand of the protein "beacon" |
| 04/17/2002 | EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 04/17/2002 | EP1196432A2 FVIIa ANTAGONISTS |
| 04/17/2002 | EP1196431A1 A substantially crystalline form of melagatran |
| 04/17/2002 | EP1196426A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 04/17/2002 | EP1196416A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196412A1 Nitrogen containing heterobicycles as factor xa inhibitors |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196410A1 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196409A2 Respiratory syncytial virus replication inhibitors |
| 04/17/2002 | EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 04/17/2002 | EP1196406A1 Amino ceramide-like compounds and therapeutic methods of use |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196403A1 Antipsychotic cyclic n-aralkyl amines |
| 04/17/2002 | EP1196400A1 Amino-alkyl derivatives |
| 04/17/2002 | EP1196397A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 04/17/2002 | EP1196396A1 Conjugates of sodium channel blockers and methods of using the same |
| 04/17/2002 | EP1196395A1 Cyclized amino acid derivatives |
| 04/17/2002 | EP1196394A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 04/17/2002 | EP1196392A1 6-carboxyphenyldihydropyridazinone derivatives and use thereof |
| 04/17/2002 | EP1196391A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 04/17/2002 | EP1196390A2 Pyrazole compositions useful as inhibitors of erk |
| 04/17/2002 | EP1196389A1 N-heterocyclic derivatives with neuronal activity |
| 04/17/2002 | EP1196384A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 04/17/2002 | EP1196383A1 Process for preparing amlodipine benzenesulphonate |
| 04/17/2002 | EP1196380A2 Indoles and indazoles for the treatment of migraine |
| 04/17/2002 | EP1196371A1 Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity |
| 04/17/2002 | EP1196194A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196188A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196187A1 Keratinocyte growth factor-2 formulations |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196176A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 04/17/2002 | EP1196174A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 04/17/2002 | EP1196172A2 Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |
| 04/17/2002 | EP1196167A1 Method of reducing neuronal injury or apoptosis |
| 04/17/2002 | EP1196166A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 04/17/2002 | EP1196162A1 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same |
| 04/17/2002 | EP1196154A2 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 04/17/2002 | EP1196141A1 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 04/17/2002 | EP1196136A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196135A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/17/2002 | EP1196047A1 Prophylactic dietary supplement based on milk |
| 04/17/2002 | EP1007561B1 Novel conjugates of opioids and endogenous carriers |
| 04/17/2002 | EP0998475B1 Novel compounds |
| 04/17/2002 | EP0996620B1 Novel compounds |
| 04/17/2002 | EP0934290B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 04/17/2002 | EP0915702B1 Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| 04/17/2002 | EP0912086A4 Regulation of alzheimer's disease related proteins and uses thereof |
| 04/17/2002 | EP0880519B1 Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them |
| 04/17/2002 | EP0866699B1 The use of cholinesterase inhibitors for the manufacture of a medicament for the treatment of xerostomia |
| 04/17/2002 | EP0831911B1 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| 04/17/2002 | EP0831902A4 Muscle trophic factor |
| 04/17/2002 | EP0804186B1 Indole diterpene alkaloid compounds |
| 04/17/2002 | EP0794790B1 Localized delivery of factors enhancing survival of transplanted cells |
| 04/17/2002 | EP0676951B1 Use of vitamin d glycosides for the treatment or prevention of osteoporosis |
| 04/17/2002 | EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids |
| 04/17/2002 | EP0607178B1 Methods for the isolation and fusion of cells |
| 04/17/2002 | EP0500785B1 A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345334A Antibodies specific to KDR and uses thereof |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345319A Triazole compounds with dopamine-D3-receptor affinity |
| 04/17/2002 | CN1345318A Triazole compounds with dopamine -D3-receptor affinity |
| 04/17/2002 | CN1345317A (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for production thereof and pharmaceutical compositions containing the same |
| 04/17/2002 | CN1345314A Amine derivatives as protease inhibitors |
| 04/17/2002 | CN1345312A Dibenzoazulene derivatives for treating thrombosis, osteoporosis arteriosclerosis |
| 04/17/2002 | CN1345308A Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors |
| 04/17/2002 | CN1345307A N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 04/17/2002 | CN1345303A Oxamic acids and derivatives as thyroid receptor ligands |
| 04/17/2002 | CN1345247A Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas |
| 04/17/2002 | CN1345245A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/17/2002 | CN1345239A Heterocyclic containing biphenyl alpha P2 inhibitors and method |
| 04/17/2002 | CN1345238A Method for treatment of neurological or neuropsychiatric disorders |
| 04/17/2002 | CN1345224A Composition for cosmetic and dermatological skin care |
| 04/17/2002 | CN1344745A Martentoxin as one great-conductance calcium-activating potassium channel blocker and its prepn and use |
| 04/17/2002 | CN1344562A Externally used cold-evil expelling prepn |
| 04/17/2002 | CN1344543A 平衡液 Balanced solution |